This article is more than 5 years old. Information may no longer be current.
Top 6 updates in rheumatoid arthritis from the EULAR Annual Congress
Researchers presented data and clinical updates at the EULAR Annual Congress in London.
Coverage from the Healio Rheumatology team featured news from the conference, onsite video interviews with leading experts and research implications on patient care and practice.
Healio Internal Medicine presents the six most-viewed stories from EULAR 2016.
Baricitinib inhibits progressive radiographic joint damage in rheumatoid arthritis
Treatment of rheumatoid arthritis with baricitinib inhibited progressive radiographic joint damage compared with placebo.
“These findings have shown us that, for people with rheumatoid arthritis, baricitinib may, if approved, offer an oral option which could help them restrict joint damage over an extended period of time,” said Désirée van der Heijde, MD, PhD, of Leiden University Medical Center, the Netherlands. Read more.
Study: Systemic ultrasound in the management of early rheumatoid arthritis is not justified
The systemic use of ultrasound in the follow-up of patients with early rheumatoid arthritis is not justified, based on results of the ARCTIC trial.
“Subclinical inflammation can be treated, and strategies targeting imaging remission are feasible,” Espen A. Haavardsholm, MD, PhD, said. “However, imaging remission does not affect the treatment target and clinical remission and, as such, it is not cost-effective. Adding ultrasound information into strategic treatment and targeting the therapy toward imaging remission did not lead to improved patient outcomes.” Read more.
Antibodies to biological infliximab cross-reacted with infliximab biosimilars
Findings presented showed antibodies to infliximab in patients who received the biological treatment cross-reacted with infliximab biosimilars.
According to a press release, the findings indicate antibody-positive patients on biological infliximab should not be switched to treatment using the biosimilar. Read more.
A look at results from phase 3 studies of baricitinib for RA treatment
Peter C. Taylor, MA, PhD, FRCP, discussed a study that looked at phase 3 studies of baricitinib. He said the patient-reported outcomes showed there were statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis. Watch here.
Rituximab biosimilar shows pharmacokinetic bioequivalence in patients with RA
GP2013, a proposed rituximab biosimilar, demonstrated pharmacokinetic bioequivalence to rituximab in patients with rheumatoid arthritis. Read more.
Pharmacokinetic bioequivalence found between biosimilar, etanercept
GP2015, a proposed etanercept biosimilar, showed pharmacokinetic bioequivalence with etanercept in healthy patients. Read more.